Kyoto Drug Discovery and Development Co.,Ltd
- Biotech or pharma, therapeutic R&D
Kyoto Drug Discovery & Development Co., Ltd. (KDDD) is a clinical-stage biotech company originating from Kyoto University in Japan. Its lead compound, KUS121, is a novel neuroprotective agent that preserves cellular energy and prevents cell death. Initially developed for Central Retinal Artery Occlusion (CRAO)—a sight-threatening emergency with no approved therapies—KUS121 has shown promising efficacy. The program has received both Orphan Drug and Fast Track Designation from the FDA. With broad potential in ophthalmology and beyond, KDDD is advancing transformative therapies for serious unmet medical needs.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}